Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase

Yohei Doi, David L. Paterson, Jennifer M. Adams-Haduch, Hanna E. Sidjabat, Alexandra O'Keefe, Andrea Endimiani, Robert A. Bonomo

研究成果: Article

21 引用 (Scopus)

抜粋

Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.

元の言語English
ページ(範囲)3159-3161
ページ数3
ジャーナルAntimicrobial agents and chemotherapy
53
発行部数7
DOI
出版物ステータスPublished - 01-07-2009
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

フィンガープリント Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用